Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David O'Reilly

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Irish Journal of Medical Science|April 22, 2022
Cost and public reimbursement of cancer medicines in the UK and the Republic of IrelandDavid O'Reilly, Ronan McLaughlin, Cian Ronayne, et al.
JMIR Research Protocols|February 18, 2026
Effectiveness and Cost-Effectiveness of Emergency Department-Based Violence Intervention Programs in the United Kingdom: Protocol for a Quasi-Experimental StudySimon Moore, Sinead Brophy, Amrita Bandyopadhyay, et al.
Irish Journal of Medical Science|January 15, 2021
Virtual oncology clinics during the COVID-19 pandemicDavid O'Reilly, Hailey Carroll, Mairi Lucas, et al.
International Journal of Dermatology|September 12, 2025
Cutaneous Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ MalignanciesDavid O'Reilly, Gregg Murray, Orla M Fitzpatrick, et al.
Biomedicines|June 26, 2025
Prognostic Significance of Delays in Initiation of Adjuvant Trastuzumab-Based Therapy in Patients with HER2-Positive Breast CancerGavin P Dowling, Aisling Hegarty, Gordon R Daly, et al.
The Oncologist|June 21, 2024
Quality of life in women with early-stage and metastatic hormone receptor-positive, HER2-negative breast cancer receiving endocrine therapyDavid O'Reilly, Abdul Rehman Farooq, Paul Nevins Selvadurai, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2025
Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN studyDavid O'Reilly, Anthony O'Grady, Conor Hayes, et al.
Breast Cancer Research and Treatment|June 14, 2021
Pregnancy-associated breast cancer: evaluating maternal and foetal outcomes. A national studyLisa Prior, Richard O'Dwyer, Abdul Rehman Farooq, et al.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexityAlessio Cortellini, Edoardo Garbo, Giulia La Cava, et al.
Journal for Immunotherapy of Cancer|February 4, 2025
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registryAlessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Irish Journal of Medical Science|April 22, 2022
Cost and public reimbursement of cancer medicines in the UK and the Republic of IrelandDavid O'Reilly, Ronan McLaughlin, Cian Ronayne, et al.
JMIR Research Protocols|February 18, 2026
Effectiveness and Cost-Effectiveness of Emergency Department-Based Violence Intervention Programs in the United Kingdom: Protocol for a Quasi-Experimental StudySimon Moore, Sinead Brophy, Amrita Bandyopadhyay, et al.
Irish Journal of Medical Science|January 15, 2021
Virtual oncology clinics during the COVID-19 pandemicDavid O'Reilly, Hailey Carroll, Mairi Lucas, et al.
International Journal of Dermatology|September 12, 2025
Cutaneous Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ MalignanciesDavid O'Reilly, Gregg Murray, Orla M Fitzpatrick, et al.
Biomedicines|June 26, 2025
Prognostic Significance of Delays in Initiation of Adjuvant Trastuzumab-Based Therapy in Patients with HER2-Positive Breast CancerGavin P Dowling, Aisling Hegarty, Gordon R Daly, et al.
The Oncologist|June 21, 2024
Quality of life in women with early-stage and metastatic hormone receptor-positive, HER2-negative breast cancer receiving endocrine therapyDavid O'Reilly, Abdul Rehman Farooq, Paul Nevins Selvadurai, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2025
Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN studyDavid O'Reilly, Anthony O'Grady, Conor Hayes, et al.
Breast Cancer Research and Treatment|June 14, 2021
Pregnancy-associated breast cancer: evaluating maternal and foetal outcomes. A national studyLisa Prior, Richard O'Dwyer, Abdul Rehman Farooq, et al.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexityAlessio Cortellini, Edoardo Garbo, Giulia La Cava, et al.
Journal for Immunotherapy of Cancer|February 4, 2025
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registryAlessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, et al.
Pageof 6